Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIGRANT: Combined Antioxidant Therapy for Migraine Prevention
NCT02629536Phase 3Unknown
- Sponsor
- University of Notre Dame Australia
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine, vitamin e and ascorbic acid in migraine, sponsored by University of Notre Dame Australia. Primary endpoint: Difference in mean number of migraine episodes per month at 16 weeks. Status: unknown.
02
Drugs
acetylcysteinevitamin eascorbic acid
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02629536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629536.